Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3049–3072 of 13,629 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Breast Cancer
Interventions: Group Counseling; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 5
States / cities: Newark, Delaware • Voorhees Township, New Jersey • Bryn Mawr, Pennsylvania + 1 more

Conditions: Malignant Melanoma
Interventions: [18F] CFA; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: VST-1001, 99mTc-labeled sulfur colloid; Drug
Lead sponsor: Vestan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Houston, Texas • Salt Lake City, Utah

Conditions: Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions: Ambulatory Blood Pressure Measurement; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Neoplasms
Interventions: Permanent Breast Seed Implant (PBSI); Radiation
Lead sponsor: Concure Oncology-Breast Microseed Inc.; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Fredericksburg, Virginia • Seattle, Washington

Conditions: Eczema, Atopic Dermatitis
Interventions: Experimental: B244; Drug
Lead sponsor: AOBiome LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Bryant, Arkansas • Los Angeles, California • Plainfield, Indiana + 3 more

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Interventions: SYNCAR-001, STK-009; Drug
Lead sponsor: Synthekine; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2041
U.S. locations: 6
States / cities: Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 3 more

Conditions: Critical Limb Ischemia
Interventions: Open surgical revascularization, Endovascular revascularization; Procedure · Device
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years and older
Enrollment: 1,843 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more

Conditions: Colorectal Cancer, Breast Cancer
Interventions: Exercise training, Metformin, Educational information; Behavioral · Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Melanoma (Skin)
Interventions: ADI-PEG-20, Pharmacology Studies; Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fibroadenoma, Breast Cancer Stage I
Interventions: Harmonic motion imaging guided focused ultrasound (HMIgFUS), Microbubble-mediated Low Intensity Focused Ultrasound (LIFU), Microbubbles; Procedure · Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Ectodermal Dysplasia, Jaw, Edentulous
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1986 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
Interventions: Lenvatinib Oral Product, Pembrolizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Myositis, Dermatomyositis
Interventions: Deucravacitinb; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Early-stage Breast Cancer, Breast Carcinoma, DCIS
Interventions: Radiation: Accelerated Partial Breast Irradiation (APBI); Radiation
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more

Conditions: Melanoma
Interventions: epothilone b; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 6
States / cities: Aurora, Colorado • Tampa, Florida • The Bronx, New York + 3 more

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, filgrastim, flu matrix peptide p58-66, gp100 antigen, recombinant MAGE-3.1 antigen, tyrosinase peptide, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Baylor Health Care System; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Herpes
Interventions: famciclovir; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms, Lung Neoplasms
Interventions: SN2310 Injectable Emulsion; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Abscess
Interventions: Bedside emergency ultrasound; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 18 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more

Conditions: Malignant Melanoma
Interventions: CP-4055, Sorafenib (Nexavar); Drug
Lead sponsor: Clavis Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year and older
Enrollment: 2,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Weight Loss
Interventions: Low Fat Diet plus exercise, Low Carbohydrate diet + Exercise; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Couple-Focused Intervention for Breast Cancer Patients

PET Imaging of the Immune System Using Analog Probes

VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

A Registry Study of Breast Microseed Treatment

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

Exercise and Metformin in Colorectal and Breast Cancer Survivors

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)

Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis

Pilot Trial of Preop Partial Radiation in Breast Cancer Patients

EPO906 Therapy in Patients With Advanced Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors

Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Genetic Analysis of Psoriasis and Psoriatic Arthritis

Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk